Bristol Myers Company Insiders
BMY Stock | USD 48.86 0.13 0.27% |
Slightly above 67% of Bristol Myers' corporate insiders are selling. The analysis of insiders' sentiment of trading Bristol Myers Squibb stock suggests that many insiders are alarmed at this time. Bristol Myers employs about 34.1 K people. The company is managed by 62 executives with a total tenure of roughly 344 years, averaging almost 5.0 years of service per executive, having 550.0 employees per reported executive.
Giovanni Caforio Chairman Chairman of the Board, Chief Executive Officer |
Lamberto Andreotti Chairman Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. Committee |
Bristol Myers' Insider Buying Vs Selling
33
Selling | Buying |
Latest Trades
2024-01-09 | Rick Larsen | Disposed @ 51.27 | |||
2024-01-03 | Tommy Tuberville | Disposed @ 52.3 | |||
2023-12-05 | Christopher S Boerner | Acquired 2000 @ 49.78 | View | ||
2023-11-28 | Christopher S Boerner | Acquired 3071 @ 48.86 | View | ||
2023-11-20 | Theodore R Samuels II | Acquired 8500 @ 49.81 | View | ||
2023-11-16 | Tommy Tuberville | Disposed @ 50.84 | |||
2023-10-24 | Greg Stanton | Disposed @ 56.12 | |||
2023-10-17 | Tommy Tuberville | Acquired @ 57.38 | |||
2023-09-26 | Greg Stanton | Acquired @ 58.54 | |||
2023-08-24 | Ann Powell | Disposed 17986 @ 61.25 | View | ||
2023-08-22 | Dan Sullivan | Disposed @ 61.86 | |||
2023-08-03 | Robert M Plenge | Disposed 732 @ 61.14 | View | ||
2023-07-12 | Daniel S. Goldman | Disposed @ 62.27 | |||
2023-05-10 | Shelley Moore Capito | Disposed @ 68.49 | |||
2023-05-03 | Rupert Vessey | Disposed 50385 @ 67.06 | View |
Monitoring Bristol Myers' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Bristol Myers' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Bristol Myers Squibb. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Bristol Myers' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Bristol |
Bristol Myers' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bristol Myers' future performance. Based on our forecasts, it is anticipated that Bristol will maintain a workforce of slightly above 44000 employees by May 2024.Bristol Myers' latest congressional trading
Congressional trading in companies like Bristol Myers Squibb, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Bristol Myers by those in governmental positions are based on the same information available to the general public.
2024-01-03 | Senator Thomas H Tuberville | Acquired Under $15K | Verify | ||
2023-10-24 | Representative Greg Stanton | Acquired Under $15K | Verify | ||
2023-05-10 | Senator Shelley M Capito | Acquired Under $15K | Verify | ||
2022-11-28 | Representative Van Taylor | Disposed $100K to $250K | Verify | ||
2022-06-17 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2022-01-18 | Senator Thomas R. Carper | Acquired Under $15K | Verify | ||
2021-11-10 | Representative Carol Devine Miller | Disposed $15K to $50K | Verify | ||
2021-10-28 | Representative Kim Schrier | Disposed Under $15K | Verify | ||
2020-11-19 | Representative Kenny Marchant | Acquired $15K to $50K | Verify | ||
2020-10-22 | Representative Katherine M. Clark | Disposed Under $15K | Verify | ||
2020-10-22 | Representative George Holding | Disposed Under $15K | Verify | ||
2020-04-16 | Senator David A Perdue , Jr | Acquired Under $15K | Verify | ||
2020-04-14 | Senator Kelly Loeffler | Acquired $100K to $250K | Verify | ||
2020-03-18 | Representative Gilbert Cisneros | Disposed Under $15K | Verify | ||
2018-12-28 | Senator Sheldon Whitehouse | Acquired $15K to $50K | Verify | ||
2018-04-17 | Representative Thomas Suozzi | Acquired Under $15K | Verify | ||
2018-04-06 | Representative Carlos Curbelo | Acquired Under $15K | Verify | ||
2017-01-20 | Senator John Hoeven | Acquired $50K to $100K | Verify | ||
2014-06-19 | Senator Susan M. Collins | Acquired Under $15K | Verify | ||
2014-06-19 | Senator Susan M Collins | Acquired Under $15K | Verify |
Bristol Myers Management Team Effectiveness
The company has Return on Asset of 0.0563 % which means that on every $100 spent on assets, it made $0.0563 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2653 %, implying that it generated $0.2653 on every 100 dollars invested. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bristol Myers' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop 0.15 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024.Net Income Applicable To Common Shares is likely to rise to about 6 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.6 B in 2024.
Bristol Myers Workforce Comparison
Bristol Myers Squibb is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 469,270. Bristol Myers holds roughly 34,100 in number of employees claiming about 7% of equities under Health Care industry.
Bristol Myers Profit Margins
The company has Net Profit Margin of 0.18 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.17 %, which entails that for every 100 dollars of revenue, it generated $0.17 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.8 | 0.7624 |
|
| |||||
Operating Profit Margin | 0.25 | 0.3831 |
|
|
Bristol Myers Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bristol Myers insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bristol Myers' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bristol Myers insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 0.5 | 1 | 2 | 3,306 | 4,502 |
2024-03-01 | 0.5746 | 77 | 134 | 1,299,044 | 887,200 |
2023-12-01 | 1.2857 | 18 | 14 | 83,482 | 50,028 |
2023-09-01 | 0.8182 | 9 | 11 | 15,264 | 75,840 |
2023-06-01 | 0.9412 | 16 | 17 | 30,303 | 89,060 |
2023-03-01 | 1.45 | 116 | 80 | 1,372,082 | 1,197,512 |
2022-12-01 | 1.7778 | 16 | 9 | 76,139 | 101,217 |
2022-09-01 | 1.1 | 11 | 10 | 135,987 | 371,874 |
2022-06-01 | 2.8571 | 20 | 7 | 33,978 | 107,629 |
2022-03-01 | 1.4583 | 105 | 72 | 1,307,363 | 965,115 |
2021-12-01 | 0.8667 | 13 | 15 | 116,346 | 240,709 |
2021-09-01 | 1.0 | 30 | 30 | 403,897 | 794,971 |
2021-06-01 | 1.1875 | 19 | 16 | 39,854 | 94,914 |
2021-03-01 | 1.2963 | 140 | 108 | 1,328,695 | 658,778 |
2020-12-01 | 0.871 | 27 | 31 | 159,284 | 298,896 |
2020-09-01 | 1.4286 | 20 | 14 | 212,460 | 316,254 |
2020-06-01 | 2.25 | 27 | 12 | 100,259 | 46,619 |
2020-03-01 | 1.1087 | 153 | 138 | 1,850,402 | 1,237,584 |
2019-12-01 | 11.5455 | 127 | 11 | 2,125,296 | 66,385 |
2019-09-01 | 14.0 | 14 | 1 | 59,752 | 220.00 |
2019-06-01 | 1.0769 | 14 | 13 | 38,923 | 86,400 |
2019-03-01 | 0.6296 | 102 | 162 | 1,359,971 | 985,222 |
2018-12-01 | 1.625 | 13 | 8 | 18,753 | 20,002 |
2018-09-01 | 1.2727 | 14 | 11 | 8,787 | 28,444 |
2018-06-01 | 1.1429 | 16 | 14 | 40,659 | 48,875 |
2018-03-01 | 1.2887 | 125 | 97 | 1,126,758 | 794,390 |
2017-12-01 | 1.7143 | 12 | 7 | 171,144 | 328,464 |
2017-09-01 | 2.2 | 11 | 5 | 12,629 | 14,064 |
2017-06-01 | 1.75 | 14 | 8 | 113,954 | 63,675 |
2017-03-01 | 0.8491 | 135 | 159 | 1,434,652 | 1,292,500 |
2016-12-01 | 1.2 | 12 | 10 | 693,487 | 698,400 |
2016-09-01 | 0.6111 | 11 | 18 | 12,728 | 83,007 |
2016-06-01 | 0.5161 | 16 | 31 | 451,189 | 996,398 |
2016-03-01 | 1.1687 | 194 | 166 | 2,351,206 | 1,432,759 |
2015-12-01 | 0.4375 | 7 | 16 | 5,329 | 119,816 |
2015-09-01 | 0.8333 | 10 | 12 | 321,192 | 657,916 |
2015-06-01 | 0.5 | 6 | 12 | 34,707 | 80,775 |
2015-03-01 | 1.3793 | 200 | 145 | 2,213,345 | 1,889,360 |
2014-12-01 | 0.6154 | 8 | 13 | 25,235 | 384,689 |
2014-09-01 | 0.5556 | 10 | 18 | 90,304 | 353,237 |
2014-06-01 | 1.25 | 10 | 8 | 37,893 | 41,449 |
2014-03-01 | 1.4214 | 226 | 159 | 2,383,819 | 2,529,455 |
2013-12-01 | 1.3333 | 8 | 6 | 46,035 | 35,251 |
2013-09-01 | 1.125 | 9 | 8 | 24,861 | 184,595 |
2013-06-01 | 0.4091 | 27 | 66 | 1,148,469 | 2,830,626 |
2013-03-01 | 1.1554 | 223 | 193 | 2,658,929 | 3,053,939 |
2012-12-01 | 0.3056 | 11 | 36 | 589,294 | 1,054,973 |
2012-09-01 | 0.3333 | 16 | 48 | 965,673 | 2,041,572 |
2012-06-01 | 0.1786 | 5 | 28 | 20,745 | 153,556 |
2012-03-01 | 1.2891 | 165 | 128 | 1,901,514 | 1,279,129 |
2011-12-01 | 0.4375 | 7 | 16 | 502,411 | 1,106,499 |
2011-09-01 | 1.1667 | 7 | 6 | 729,052 | 726,921 |
2011-06-01 | 0.2444 | 11 | 45 | 1,255,062 | 3,022,207 |
2011-03-01 | 0.9188 | 147 | 160 | 2,320,390 | 1,794,777 |
2010-12-01 | 0.8333 | 5 | 6 | 13,585 | 56,533 |
2010-09-01 | 0.4074 | 11 | 27 | 252,545 | 912,952 |
2010-06-01 | 0.5333 | 8 | 15 | 84,718 | 495,254 |
2010-03-01 | 0.8362 | 97 | 116 | 1,986,576 | 1,572,207 |
2009-12-01 | 0.25 | 4 | 16 | 1,418 | 101,868 |
2009-09-01 | 0.5714 | 4 | 7 | 4,357 | 37,305 |
2009-06-01 | 1.2 | 6 | 5 | 43,455 | 12,830 |
2009-03-01 | 1.1831 | 84 | 71 | 4,628,862 | 820,311 |
2008-12-01 | 1.2 | 6 | 5 | 64,226 | 68,195 |
2008-09-01 | 0.375 | 3 | 8 | 1,579 | 48,764 |
2008-06-01 | 3.4545 | 38 | 11 | 418,379 | 406,408 |
2008-03-01 | 1.5 | 48 | 32 | 2,925,474 | 32,790 |
2007-12-01 | 3.0 | 6 | 2 | 2,757 | 19,399 |
2007-09-01 | 0.5455 | 6 | 11 | 2,802 | 51,486 |
2007-06-01 | 0.68 | 17 | 25 | 638,391 | 201,683 |
2007-03-01 | 2.0 | 36 | 18 | 1,135,518 | 25,011 |
2006-12-01 | 7.5 | 15 | 2 | 1,839,149 | 6,076 |
2006-09-01 | 0.7273 | 8 | 11 | 5,478 | 78,666 |
2006-06-01 | 1.3 | 13 | 10 | 22,389 | 15,850 |
2006-03-01 | 1.6739 | 77 | 46 | 2,113,360 | 611,800 |
2005-12-01 | 2.2 | 11 | 5 | 266,812 | 40,141 |
2005-09-01 | 2.5 | 10 | 4 | 209,934 | 3,986 |
2005-06-01 | 2.0 | 20 | 10 | 83,508 | 29,934 |
2005-03-01 | 3.4667 | 52 | 15 | 1,929,595 | 364,819 |
2004-12-01 | 2.25 | 9 | 4 | 37,649 | 13,165 |
2004-09-01 | 1.7143 | 12 | 7 | 158,149 | 112,791 |
2004-06-01 | 3.0 | 21 | 7 | 44,649 | 21,954 |
2004-03-01 | 6.1111 | 55 | 9 | 1,850,467 | 208,601 |
2003-12-01 | 9.0 | 9 | 1 | 24,904 | 5,127 |
2003-09-01 | 6.6667 | 20 | 3 | 414,912 | 52,034 |
1998-03-01 | 0.4 | 4 | 10 | 72,750 | 126,648 |
Bristol Myers Notable Stakeholders
A Bristol Myers stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bristol Myers often face trade-offs trying to please all of them. Bristol Myers' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bristol Myers' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Giovanni Caforio | Chairman of the Board, Chief Executive Officer | Profile | |
Lamberto Andreotti | Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. Committee | Profile | |
Adam Dubow | Senior Vice President, Chief Compliance Officer and Ethics Officer, Member of the Leadership Team | Profile | |
John Elicker | Senior Vice President - Corporate Affairs and Investor Relations | Profile | |
Karen Santiago | Senior Vice President, Corporate Controller | Profile | |
Rupert Vessey | Executive Vice President - Research and Early Development, Member of the Leadership Team | Profile | |
Emmanuel Blin | Senior Vice President Chief Strategy Officer | Profile | |
Joseph Caldarella | Senior Vice President Corporate Controller | Profile | |
Murdo Gordon | Executive Vice President Chief Commercial Officer | Profile | |
Ann Judge | Chief Human Resource Officer, Senior Vice President Member of the Leadership Team | Profile | |
Sandra Leung | Executive Vice President, General Counsel, Member of the Leadership Team | Profile | |
Paul Autenried | Executive Vice President, Chief Information Officer, Member of the Leadership Team | Profile | |
Samit Hirawat | Executive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership Team | Profile | |
Francis Cuss | Executive Vice President Chief Scientific Officer | Profile | |
Paul Biondi | Senior Vice President, Head of Strategy & Business Development | Profile | |
Kathryn Metcalfe | Executive Vice President - Corporate Affairs Member of the Leadership Team | Profile | |
Elizabeth Mily | Executive Vice President - Strategy and Business Development, Member of the Leadership Team | Profile | |
Ann Powell | Chief Human Resource Officer, Senior Vice President, Member of the Leadership Team | Profile | |
Charles Bancroft | Chief Financial Officer, Executive Vice President - Global Business Operations | Profile | |
Louis Schmukler | Executive Vice President, President - Global Product Development and Supply, Member of the Leadership Team | Profile | |
Christopher Boerner | Executive Vice President and Chief Commercial Officer, Member of the Leadership Team | Profile | |
David Elkins | Executive Vice President and Chief Financial Officer Member of the Leadership Team | Profile | |
Anne Nielsen | Senior Vice President Chief Compliance and Ethics Officer | Profile | |
Joseph Eid | Senior Vice President and Head of Global Medical Affairs, Member of the Leadership Team | Profile | |
Thomas Lynch | Chief Scientific Officer, Executive Vice President | Profile | |
Samuel Moed | Senior Vice President - Strategic Planning and Analysis | Profile | |
Togo West | Independent Director | Profile | |
Michael Bonney | Independent Director | Profile | |
Alan Lacy | Independent Director | Profile | |
Robert Bertolini | Independent Director | Profile | |
Jose Baselga | Independent Director | Profile | |
Michael Grobstein | Independent Director | Profile | |
Phyllis Yale | Independent Director | Profile | |
Matthew Emmens | Independent Director | Profile | |
Peter Arduini | Independent Director | Profile | |
Karen Vousden | Independent Director | Profile | |
Gerald Storch | Independent Director | Profile | |
Vicki Sato | Lead Independent Director | Profile | |
Manuel Medina | Independent Director | Profile | |
Julia Haller | Independent Director | Profile | |
Laurie Glimcher | Independent Director | Profile | |
Lewis Campbell | Independent Director | Profile | |
Dinesh Paliwal | Independent Director | Profile | |
Theodore Samuels | Lead Independent Director | Profile | |
Adam Lenkowsky | Chief VP | Profile | |
Jitendra Tyagi | Head India | Profile | |
Catherine Owen | Senior Markets | Profile | |
BCH BM | Ex Devel | Profile | |
Nadim Ahmed | Executive Vice President and President - Hematology | Profile | |
Cari Gallman | VP Officer | Profile | |
Ahn Poole | Executive Officer | Profile | |
Tim Power | Vice President of Investor Relations | Profile | |
Giovanni MD | Executive Board | Profile | |
Greg Meyers | Executive Vice President Chief Digital and Technology Officer, Member of the Leadership Team | Profile | |
Michelle Weese | Executive Vice President - Corporate Affairs, Member of the Leadership Team | Profile | |
Joseph Eiden | Head Affairs | Profile | |
Paula Price | Independent Director | Profile | |
Sandra Esq | Executive Counsel | Profile | |
Kimberly Jablonski | Chief Officer | Profile | |
Derica Rice | Independent Director | Profile | |
Timothy Power | VP Relations | Profile | |
Samit MD | Executive Development | Profile |
About Bristol Myers Management Performance
The success or failure of an entity such as Bristol Myers Squibb often depends on how effective the management is. Bristol Myers management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bristol management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bristol management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.17 | 0.15 | |
Return On Capital Employed | 0.24 | 0.29 | |
Return On Assets | 0.08 | 0.14 | |
Return On Equity | 0.27 | 0.30 |
The data published in Bristol Myers' official financial statements usually reflect Bristol Myers' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bristol Myers Squibb. For example, before you start analyzing numbers published by Bristol accountants, it's critical to develop an understanding of what Bristol Myers' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Bristol Myers' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bristol Myers' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bristol Myers' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myers Squibb. Please utilize our Beneish M Score to check the likelihood of Bristol Myers' management manipulating its earnings.
Bristol Myers Workforce Analysis
Traditionally, organizations such as Bristol Myers use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bristol Myers within its industry.Bristol Myers Manpower Efficiency
Return on Bristol Myers Manpower
Revenue Per Employee | 1.3M | |
Revenue Per Executive | 725.9M | |
Net Income Per Employee | 235.8K | |
Net Income Per Executive | 129.7M | |
Working Capital Per Employee | 278.8K | |
Working Capital Per Executive | 153.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.